The analyst community agrees, anyway. Undeterred by political rhetoric and handwringing, most of them still consider First ...

Shares of biotech Intellia Therapeutics ( NTLA 5.18%) are down by around 33% over the past 30 days, amid the publication of ...

From there, the case for or against investing in Lilly should become much clearer. Eli Lilly's earnings report ...

Alas, this master plan is now in serious doubt. On Nov. 11, the pharmaceutical giant reported that emraclidine failed to meet ...

The top headline in the semiconductor industry this week was the latest quarterly earnings report from artificial ...

Investors should buy the postelection dip in renewable energy names given a cheap entry point and surging power demand from ...

Stock prices used were the afternoon prices of Nov. 6, 2024. The video was published on Nov. 8, 2024. Should you invest $1,000 in Celsius right now? Before you buy stock in Celsius, consider this ...

The decline in Wynn stock since "soft" 3Q results opens up an opportunity to buy undervalued assets. Click here to read more ...

The market reaction appears excessive and presents a ... was worth more than 10% of ABBV's valuation in my view. I'm rating ...

Emraclidine was added to AbbVie’s pipeline with this year’s acquisition of Cerevel and was a key reason for AbbVie to buy the ... to play the stock after the recent price dip.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies ... now is the best time to buy before it’s too late. And the numbers speak for ...